Novo Nordisk settles patent infringement lawsuit with Novartis
Shortly before a trial was meant to begin, Novo Nordisk and Sandoz have settled a patent infringement case concerning diabetes drug Victoza, meaning the generic drugmaker isn’t allowed to launch its intended copy version before June 2024.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen & catherine brett
The two pharmaceutical firms, Novo Nordisk and Novartis-owned Sandoz, have come to an agreement out of court, meaning that Sandoz will hold off on the launch of its generic version of the Danish firm’s blockbuster insulin analog, Victoza (liraglutide), industry media Fierce Pharma writes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk sues Teva over generic drug development
For subscribers
Novo Nordisk initiates patent suit to stop Ozempic copies
For subscribers
Lundbeck preps for war against generic drugmakers in US
For subscribers
